TOPLINE

Patients with obesity and psoriatic arthritis (PsA) who initiated tirzepatide concurrently with biologic therapy achieved more than triple the rate of acceptable symptom state and double the rate of minimal skin disease compared with those starting biologics alone, alongside greater weight loss and lower inflammation at 6 months.

METHODOLOGY

• Researchers conducted a propensity score-matched comparative study at tertiary care rheumatology centers in Italy to compare clinical outcomes in patients with obesity and PsA who initiated tirzepatide concurrently with biologic therapy with those initiating biologics alone.
• They enrolled patients with PsA meeting classification criteria, with BMI ≥ 30 or ≥ 27 and at least one weight-related comorbidity.
• A total of 31 patients (mean age, 56.1 years; 65% female) initiating tirzepatide (2.5 mg/wk subcutaneously, uptitrated to 5 mg/wk after 1 month) concurrently with biologic or targeted synthetic disease-modifying antirheumatic drug therapy were prospectively enrolled from January 2025 and matched with 62 control individuals (mean age, 54.8 years; 61% female) who initiated biologics alone (2021–2025).
• Outcomes at 6 months included minimal disease activity (MDA), Disease Activity Index for Psoriatic Arthritis (DAPSA) low disease activity (LDA ≤ 14), PsA Impact of Disease-12 (PsAID-12) Patient Acceptable Symptom State (PASS ≤ 4), Health Assessment Questionnaire (HAQ) ≤ 0.5, Psoriasis Area and Severity Index (PASI ≤ 1), Visual Analogue Scale (VAS) pain, and C-reactive protein (CRP).

TAKEAWAY

• At 6 months, the tirzepatide group demonstrated significantly greater reduction in BMI (−2.9 vs +0.4), with 94% achieving ≥ 5% weight loss, and significantly lower CRP (4.2 vs 7.7 mg/L; P < .001 for both).
• Patients treated with tirzepatide were 3.44 times more likely to achieve PsAID-12 PASS ≤ 4 (odds ratio [OR], 3.44; P = .009), 2.59 times more likely to achieve PASI ≤ 1 (OR, 2.59; P = .045), and 3.27 times more likely to achieve HAQ ≤ 0.5 (OR, 3.27; P = .022) than those receiving biologics alone.
• The rates of achieving MDA and DAPSA LDA did not differ significantly between the groups.
• Tirzepatide was discontinued by 14% of patients, and gastrointestinal adverse events were common but generally manageable among those who remained on treatment.

IN PRACTICE

"[These] data provide preliminary real-world evidence supporting concurrent GIP [Glucose-dependent Insulinotropic Polypeptide]/GLP-1 RA [receptor agonist] initiation with biologics in obese PsA," the authors wrote. "Addressing obesity pharmacologically at biologic initiation may represent a potential paradigm shift in managing this challenging population," they added.

SOURCE

The study was led by Vincenzo Venerito, Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro in Bari, Italy. It was published online on July 30 as a short report in RMD Open.

LIMITATIONS

No formal power calculation was performed; post hoc power for MDA was only 0.21. Patients self-funded tirzepatide, introducing potential socioeconomic confounding and expectation bias that disproportionately affects patient-reported measures. A 6-month follow-up period may be too short to capture the full impact of sustained weight loss on composite disease outcomes.

DISCLOSURES

The authors did not declare any specific funding for this research. No relevant conflicts of interest were disclosed by the authors.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.